[PDF] Top 20 Targeted therapy in melanoma
Has 10000 "Targeted therapy in melanoma" found on our website. Below are the top 20 most common "Targeted therapy in melanoma".
Targeted therapy in melanoma
... the melanoma patients, five of the seven with BRAF V600E treated at 240 mg bid had tumor regres- sion, with one confirmed PR and one unconfirmed PR; two of four patients with unknown V600E status had tumor ... See full document
10
Targeted Therapy for Cutaneous Melanoma: Beyond BRAF...
... metastatic melanoma patients with activating BRAF mutations has demonstrated that personalized targeted therapy strategies can provide significant clinical benefit in this highly aggressive ... See full document
10
MicroRNAs induced in melanoma treated with combination targeted therapy of Temsirolimus and Bevacizumab
... A limitation of this study is the modest number of pa- tients enrolled and studied, which was constrained by the sample size of the phase II clinical trial [12]. The accrual goal was 20; the actual accrual was slightly ... See full document
12
Update on benefit of immunotherapy and targeted therapy in melanoma: the changing landscape
... in melanoma, but also in other tumor types, such as renal cell carcinoma, non-small-cell lung cancer, gastric cancer, and prostate ...novel targeted immunotherapies have substantial positive effects on the ... See full document
11
Co-existence of BRAF and NRAS driver mutations in the same melanoma cells results in heterogeneity of targeted therapy resistance
... to targeted therapy, we could see a strong, well-supported monophyletic evolution of metastases following both BRAF and MEK inhibitor treatment and relapse with phylogenetic analysis ... See full document
12
BRD4-targeted therapy induces Myc-independent cytotoxicity in Gnaq/11-mutatant uveal melanoma cells
... melanoma, as 85% of primary and metastatic UM carry oncogenic mutations of G-protein α-subunits q or 11 [16, 17], and have a high tendency to metastasize to the liver [18]. Recent efforts in the understanding of ... See full document
13
Is there still a role for cytotoxic chemotherapy after targeted therapy and immunotherapy in metastatic melanoma? A case report and literature review
... Finally, to answer these questions, a retrospective mutation-based study could be used to evaluate the response rate of metastatic melanomas to different thera- peutic modalities according to each individual muta- tion. ... See full document
5
A targeted therapy for melanoma by graphene oxide composite with microRNA carrier
... ing melanoma, a combination of graphene oxide (GO), chitosan (CS), and a cellular penetrating peptide, MPG, was prepared with solid dispersion method in this ...inhibiting melanoma cells was ... See full document
12
Pathological complete response induced by neoadjuvant treatment using BRAF and MEK inhibitors in a patient with unresectable BRAF V600E-mutant malignant melanoma of the gallbladder
... gallbladder melanoma. The impressive response suggests that presurgical targeted therapy may be combined with surgery to achieve long-term ... See full document
6
Neoadjuvant therapy for locally advanced melanoma: new strategies with targeted therapies
... cutaneous melanoma, primarily because effec- tive medical treatments for this disease have been ...advanced melanoma and anecdotal cases of this approach with the use of biologic ...neoadjuvant ... See full document
7
Treating advanced melanoma: current insights and opportunities
... Individualized targeted therapy shows response rates that have never been described in melanoma ...various targeted substances. Combined therapy leads to increased response rates, but ... See full document
8
Novel melanoma therapy
... BRAF targeted therapy were assigned 1:1:1 to receive dabrafenib (150 mg QD) and trametinib (either 1 or 2 mg QD) or dabrafenib (150 mg QD) ...IV melanoma patients with BRAF V600E or V600K mutation ... See full document
10
A Rare Case of Small Bowel Intussusception Due to Metastatic Malignant Melanoma
... obstructive melanoma lesions was successful, his quality of life was dramatically improved followed by the resumption of treatment with ...tastatic melanoma, including immune checkpoint inhibitors and ... See full document
6
<p>Treatment of Advanced/Metastatic Melanoma in the United States and Western Europe: Results of the CancerMPact Survey</p>
... systemic therapy had been shown to signi fi cantly improve overall survival (OS) for patients with advanced or metastatic melanoma based on results from randomized clinical ...metastatic melanoma, ... See full document
7
Personalized comprehensive molecular profiling of high risk osteosarcoma: Implications and limitations for precision medicine
... like melanoma have frequent aberrations of the BRAF gene in more than 50% of patients and have three US FDA approved drugs targeting the BRAF V600 E ...given targeted therapy after chemotherapy ... See full document
13
<em>NRAS</em>-mutant melanoma: current challenges and future prospect
... disseminated melanoma. The clinical success of BRAF-targeted therapy and immunotherapy with high responders and long survivors suggests that short- and long-term disease control can be a reality for ... See full document
7
Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis.
... mucosal melanoma, versus a higher percentage of males in patients with cutaneous ...mucosal melanoma in our study had elevated LDH compared to patients with cutaneous ...mucosal melanoma than in ... See full document
36
Targeted therapy in lymphoma
... achieving at least a PR after completing 6 cycles of the VcR-CVAD were offered maintenance rituximab therapy for 5 years. All 30 enrolled patients had completed the induction phase of the VcR-CVAD chemotherapy at ... See full document
10
Metastatic chromophobe renal cell carcinoma treated with targeted therapies: A Renal Cross Channel Group study
... Time to Treatment Failure was calculated for 61 patients. The median TTF from date of first-line therapy for mChRCC was 7.2 months (95%CI: 4.1-9.5). Median TTF was 8.7 months (95%CI: 5.2-10.9) and 1.9 months ... See full document
25
Advances in the targeted therapy of liposarcoma
... Abstract: Liposarcoma (LPS) is the most common type of soft-tissue sarcoma. Complete surgical resection is the only curative means for localized disease; however, both radiation and conventional cytotoxic chemotherapy ... See full document
12
Related subjects